Core A-Pathology Core

核心 A-病理学核心

• 批准号: 10170993
• 负责人: Huamin Wang
• 金额: $ 17.5万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10170993
• 关键词: Alleles; Archives; Autopsy; Bioinformatics; Biological; Biological Assay; Biology; Cell Culture Techniques; Cell Line; Clinical; Coculture Techniques; Collaborations; Collection; Complex; Consultations; Credentialing; Data; Engineering; Epithelial; Equus caballus; Evaluation; Experimental Models; Fibroblasts; Foundations; Generations; Genes; Genetic; Genetically Engineered Mouse; Genotype; Goals; Histologic; Histology; Histopathology; Human; Image Analysis; Immune; Immune response; Immunocompetent; Immunofluorescence Immunologic; In Situ Hybridization; Infrastructure; Injections; Institution; Investigational Therapies; Maintenance; Malignant Neoplasms; Modeling; Molecular; Molecular Abnormality; Moon; Morphology; Mus; Mutation; Neoadjuvant Therapy; Neoplasms; Nodal; Organoids; Outcome; Pancreas; Pancreatic Ductal Adenocarcinoma; Pancreatic duct; Pathologic; Pathology; Patients; Phenotype; Play; Publications; Research; Research Personnel; Resected; Resources; Role; Sampling; Scanning; Services; Signal Pathway; Slide; Stromal Cells; Stromal Neoplasm; Supervision; Technical Expertise; Technology; Therapeutic; Therapeutic Intervention; Tissue Harvesting; Tissue Microarray; Tissue Sample; Tissues; University of Texas M D Anderson Cancer Center; Validation; Work; cancer genomics; cell type; chemotherapy; cohort; dimensional analysis; experimental study; genomic platform; high dimensionality; human tissue; in vivo; interest; multidimensional data; neoplastic; neoplastic cell; novel; pancreatic ductal adenocarcinoma cell; pancreatic ductal adenocarcinoma model; pancreatic neoplasm; patient derived xenograft model; pre-clinical assessment; preclinical study; quantitative imaging; repository; single-cell RNA sequencing; stem; tumor; tumor microenvironment; virtual

Core A (Pathology Core) - Abstract/Summary The study of pancreatic ductal adenocarcinoma (PDAC) presents unique challenges given its formidably complex histopathology, the many diverse cell types of the tumor microenvirionment (TME), myriad genetic abnormalities and associated biological impact, and practical limitations of tissue availability and quality. Our pathology team, with its deep expertise in mouse and human PDAC, has played a central and essential role in the pathologic analysis of virtually all experiments of this P01 since its inception. Broadly speaking, these activities include evaluation of genetically engineered mice (GEM), including mice with temporally regulated, compartment-specific disruption in epithelial and / or stromal components; analyses of tumor promoting signaling pathways with cell-type specific localization to either neoplastic cells per se, or within the host response in the TME; identification and multi-dimensional assessments of cellular components within the TME; and the cross- species validation of observations between GEM models and human tumor samples. The Pathology Core will continue to collect, maintain, archive and record all human and mouse PDAC-associated biological resources. These materials include organoids created from primary and metastatic human and mouse PDAC, and a repository of annotated low-passage PDAC cell lines. Core A will work in close collaboration with the Project Investigators to achieve three specific aims: i) to provide histology services and consultative expertise, including centralized review in the pathologic evaluation of mouse and human pancreatic neoplasms; ii) to provide infrastructure and technical expertise for a variety of immunohistochemical, immunofluorescent and in situ hybridization assays with quantitative image analysis; and iii) to generate, characterize and maintain organoid models, as well as early passage tumor and stromal cells cultures for use by the Projects as well as for allele engineering in The Modeling & Experimental Therapeutics Core. A testament to this Core’s progress stems from the creation of >165 PDXs and >30 low passage PDAC cell lines during the previous cycle. Core A’s leader is Dr. Huamin Wang at MDACC, joined by Co-Investigators Drs. Anirban Maitra and Michael Kim- bring long- standing expertise, numerous P01 collaborations and a strong publication record in the histopathological and molecular assessment of human and murine PDAC tissues. Core A will build upon the strong foundation of prior and many ongoing interactions between investigators in order to facilitate a highly successful P01 outcome.

核心 A（病理学核心）- 摘要/总结 胰腺导管腺癌 (PDAC) 的研究面临着独特的挑战，因为它具有巨大的临床意义。 复杂的组织病理学、肿瘤微环境（TME）的多种不同细胞类型、无数的遗传因素 异常和相关的生物学影响，以及组织可用性和质量的实际限制。我们的 病理学团队在小鼠和人类 PDAC 方面拥有深厚的专业知识，在 自 P01 诞生以来几乎所有实验的病理分析。从广义上讲，这些 活动包括评估基因工程小鼠（GEM），包括具有时间调节的小鼠， 上皮和/或基质成分的区室特异性破坏；肿瘤促进信号分析 具有细胞类型特异性定位于肿瘤细胞本身或宿主反应内的途径 TME； TME 内细胞成分的识别和多维评估；和交叉 GEM 模型和人类肿瘤样本之间观察结果的物种验证。病理学核心将 继续收集、维护、归档和记录所有人类和小鼠 PDAC 相关生物资源。 这些材料包括由原发性和转移性人类和小鼠 PDAC 创建的类器官，以及 带注释的低传代 PDAC 细胞系存储库。核心 A 将与该项目密切合作 研究人员要实现三个具体目标：i) 提供组织学服务和咨询专业知识，包括 小鼠和人类胰腺肿瘤病理评估的集中审查； ii) 提供 各种免疫组织化学、免疫荧光和原位的基础设施和技术专业知识 具有定量图像分析的杂交测定； iii) 生成、表征和维护类器官 模型以及供项目和等位基因使用的早期传代肿瘤和基质细胞培养物 建模与实验治疗核心工程。该核心进步的证明源于 在上一个周期中创建 >165 个 PDX 和 >30 个低传代 PDAC 细胞系。核心A的领导者是 MDACC 的 Huamin Wang 博士和联合研究员 Drs. Anirban Maitra 和 Michael Kim-带来长久- 长期的专业知识、大量的 P01 合作以及在组织病理学和 人类和小鼠 PDAC 组织的分子评估。核心 A 将建立在先前的坚实基础之上 以及研究者之间的许多持续互动，以促进 P01 取得高度成功的结果。